Brought to you by 
BI adds to cancer pipeline with CureVac’s mRNA vaccine CV9202
07 Jan 2016
Executive Summary
CureVac GMBH (oncology and infectious disease mRNA therapeutics) licensed Boehringer Ingelheim GMBH exclusive worldwide rights to its Phase I mRNA vaccine CV9202 for lung cancer.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com